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Introduction 
Patellar tendinosis (PT) is a clinical syndrome characterised by 
anterior knee pain and tenderness at the insertion of the patel­
lar tendon on the inferior pole of the patella. Commonly known 
as “jumper’s knee”, PT causes pain following repetitive running 
or jumping exercises, which usually settles with rest but returns 
when exercise is recommenced1). A cross­sectional study by Lian 
et al.2) showed that 22% of the 613 interviewed athletes either cur­
rently had symptoms of PT (14%) or had previously experienced 
symptoms of PT (8%). The prevalence of PT varied significantly 
between sports: volleyball and basketball showed the highest 
prevalence with 45% and 32% of participants affected, respec­
tively; however, cycling had none, suggesting a relation to sports 
requiring high speed and power of the knee extensors.
PT can have a prolonged disease course, refractory to first­
line non­surgical treatments (such as patellar tendon eccentric 
exercises), which can lead to many patients requiring additional 
intervention3). Platelet­rich plasma (PRP) injections have been 
shown to be beneficial to the healing and repair process of dis­
eased or injured tendons, and have been used with promising re­
sults in tendinopathies such as epicondylitis4) and Achilles tendi­
nosis5). Uncontrolled clinical studies have reported that PRP can 
improve symptoms in PT6,7); however, before the wide use of PRP 
can be recommended, high­quality controlled research evidence 
is required8,9). Hence the aim of this study was to review the cur­
rent literature with regards to randomised controlled trials (RCTs) 
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that have compared PRP injections with other treatment options 
for PT and carry out a meta­analysis, pooling the results of such 
trials. 
Methods
A search of PubMed, EMBASE, CINAHL (Cumulative Index to 
Nursing and Allied Health Literature), and Cochrane CENTRAL 
(Central Register of Controlled Trials) was conducted from their 
year of inception to October 2015 with the keywords: “patella” 
and “platelet”, followed by a search with the keywords: “patel­
lar” and “platelet”. Broad search keywords were used, rather than 
specific terms, to ensure no articles were missed. There was no 
language limit and only fully published articles or abstracts were 
included. The Preferred Reporting Items for Systematic Review 
and Meta­Analysis10) methodology guidance was employed. Full 
texts were reviewed for relevant articles or where a decision re­
garding inclusion could not be made from the title and abstract. 
The reference list of relevant articles was also examined for any 
additional articles not identified from the database search. Stud­
ies were included if they compared the use of PRP versus any 
other treatment for PT. Single case reports, reviews, and non­
comparable studies were excluded. The methodology of the stud­
ies was carefully examined to ensure that they were true RCTs 
only. Data were extracted in a standardised manner. The com­
mon reported outcome for comparison was the Victorian Insti­
tute of Sports Assessment­Patella (VISA­P) score11), which is the 
only validated scoring system developed specifically for patella 
tendinopathy. It assesses the severity of symptoms, patient’s func­
tion, and ability to participate in sporting activities, giving a score 
from 0 (asymptomatic) to 100. The VISA­P takes into account 
patient’s pain during activities such as  squatting, lunging, sitting 
and the duration of time during training before the pain becomes 
activity limiting.
A meta­analysis of mean differences in VISA­P score was per­
formed with use of a random­effects model. Summary mean 
differences, standard errors (SEs), and 95% confidence intervals 
(CIs) were calculated. Heterogeneity was assessed using tau2, I2, Q, 
and p­values. Data were analysed with CMA ver. 2 (Biostat Inc., 
Englewood, NJ, USA).
Results
From 556 published abstracts identified, 550 were excluded for 
non­pertinence including all non­RCTs. Six studies underwent a 
full abstract review, 3 of which were rejected due to not meeting 
inclusion criteria or duplication. Three full texts were reviewed; 1 
was found to be a duplicate, which left 2 RCTs that met the inclu­
sion criteria and hence were included in the meta­analysis (Fig. 1).
The first RCT by Dragoo et al.12) in our meta­analysis com­
pared leukocyte­rich PRP injections with ultrasound guided dry 
needling of the patella tendon in the treatment of PT. Patients in 
both the test and control groups were instructed to follow a pro­
gram of eccentric exercises and had twice weekly physiotherapy 
sessions following the treatment.
The second included RCT by Vetrano et al.13) compared leuko­
cyte­rich PRP injections with focused extracorporeal shock wave 
therapy (ESWT). Both the PRP and ESWT groups were given a 
standardised stretching and muscle strengthening protocol to fol­
low for 2 weeks.
Table 1 displays demographics and definitions of the two in­
cluded studies. Both RCTs used the VISA­P questionnaire scores 
for reporting outcomes and this was the outcome utilised in the 
meta­analysis.
Meta­analysis of the two studies showed no significant differ­
Fig. 1. Literature search and methodology of selection. CINAHL: Cumu­
lative Index to Nursing and Allied Health Literature, CENTRAL: Central 
Register of Controlled Trials.
Literature search undertaken using terms
"patella", "patellar", and "platelet" in Pubmed,
EMBASE, CINAHL, CENTRAL databasesCochrane
Final inclusion for
analysis (n=2)
Studies excluded for
non-pertinence
(n=550)
Studies excluded for
duplication or
not meeting the
inclusion criteria (n=3)
Study excluded
(duplication) (n=1)
Citations identified (n=556)
Abstracts reviewed
(n=6)
Full texts
reviewed (n=3)
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ence in mean VISA­P scores between PRP injections and the 
control group at early assessment (2 or 3 months; difference in 
means, 11.9; SE, 7.4; 95% CI, –2.7 to 26.4; p=0.109) (heterogeneity, 
tau2=66.4; I2=58.2%; Q=2.39; degrees of freedom, 1; p=0.12) (Fig. 
2). However, PRP was statistically better than the control with re­
gards to VISA­P scores at longer follow­up (at 6 months or more 
than 6 months; difference in means, 12.7; SE, 4.4; 95% CI, 4.1 to 
21.3; p=0.004) (heterogeneity, tau2=0; I2=0; Q=0.172; degrees of 
freedom, 1; p=0.68) (Fig. 3).
Discussion
The most important finding in our meta­analysis is that PRP 
injections are statistically better than the control group (ESWT 
and dry needling) at longer term (6 months or more) follow­up 
suggesting that PRP is an effective and worthwhile treatment for 
PT.
PT is believed to be caused by degeneration of collagen fibres 
in the tendon, leading to micro­tearing, rather than due to an 
acute inflammatory process, which may be associated with failed 
healing due to poor vascularity within the tendon14). Current 
treatments for PT include non­surgical options, such as eccentric 
exercises, ESWT, dry needling of the tendon, and PRP injections. 
These approaches are well established and they all aim to increase 
neovascularisation and promote cell growth and collagen synthe­
sis. Chen et al.15) showed that ESWT promoted healing of Achil­
les tendonitis in rats by inducing transforming growth factor­β1 
(TGF­β1) and insulin­like growth factor 1 (IGF­1) production. 
These factors are known to play important roles in mediating cell 
proliferation and tissue regeneration of tendons. Cell proliferation 
and collagen synthesis were also found to be increased in tendons 
following ESWT in a number of papers16,17). Further studies have 
shown that ESWT can cause neovascularisation at the bone­
tendon junction due to release of certain angiogenic mediators, 
such as vascular endothelial growth factor (VEGF), endothelial 
nitric oxide synthase, and proliferating cell nuclear antigen18,19). 
Indeed a number of studies have found ESWT to be beneficial to 
patients with PT over physiotherapy alone20,21).
Dry needling of affected tendons is thought to work in a similar 
way by causing bleeding and inflammation with local release of 
beneficial growth factors22,23).
An RCT in 2006 by Bahr et al.24) showed no benefit of surgical 
tenotomy over eccentric exercises alone for the treatment of PT. 
Further studies by Peers et al.25) showed comparable results be­
tween ESWT and surgical intervention in a cross­sectional out­
come analysis for chronic patella tendinosis. Many centres now 
reserve surgical tenotomy as the last treatment option for PT due 
to inconsistent results and potential morbidity associated with 
surgery24,26).
PRP injections are also not a new concept and have been used 
since the 1970s. There are various PRP kits available; however, 
the common process involves taking a venous sample of blood 
Fig. 2. Meta­analysis of short­term outcomes. CI: confidence interval, PRP: platelet­rich plasma.
Study
Vetano et al.13)
Difference in means and 95% CI
40.00 20.00
Favours control Favours PRP
0.00 20.00 40.00
Statistics for each study
5.700
20.800
11.888
Standard
error
Upper
limit
Difference
in means
z-valueLower
limit
p-value
5.198
8.260
7.426
4.489
4.611
2.669
1.097
2.518
1.601
0.273
0.012
0.109
Variance
27.023
68.229
55.141
15.889
36.989
26.440
Meta-analysis
Dragoo et al.12)
Fig. 3. Meta­analysis of long­term outcomes. CI: confidence interval, PRP: platelet­rich plasma.
Study
Vetano et al.13)
Difference in means and 95% CI
30.00 15.00
Favours control Favours PRP
0.00 15.00 30.00
Statistics for each study
13.800
9.700
12.705
Standard
error
Upper
limit
Difference
in means
z-value p-value
5.104
8.454
4.369
2.704
1.147
2.908
0.007
0.251
0.004
Lower
limit
3.797
6.870
4.141
Variance
26.047
71.471
19.090
23.803
26.270
21.268
Meta-analysis
Dragoo et al.12)
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from the patient using a venepuncture device and a bottle con­
taining an anticoagulant to prevent platelet activation prior to 
its use. This sample is placed into a centrifuge which is spun 
resulting in separation of the whole blood contents into three lay­
ers: the top platelet rich layer containing some white blood cells 
(WBC), the intermediate “buffy” layer containing mostly WBCs, 
and the third layer rich in red blood cells. The top platelet­rich 
layer can be removed and used as leukocyte­rich PRP injections. 
A further centrifugation of the top layer and “buffy” layer can 
be done to produce a pure PRP injection27). Both studies in our 
meta­analysis used a leukocyte­rich PRP injection. 
Platelets have the potential to release growth factors, such as 
TGF­β, VEGF, platelet­derived growth factor, IGF­1, and fibro­
blast growth factor, as well as cytokines which mediate healing 
within tendons7,28,29). There have been several non­controlled 
studies reporting good outcomes with PRP use in PT. In a 31 
patient study, Filardo et al.7) found a statistically significant im­
provement in sport activity levels at the end of a course of PRP 
injections in patients with chronic refractory PT compared to 
those treated with physiotherapy alone. In a prospective study by 
Kon et al.6), 20 male athletes with refractory PT underwent PRP 
injections and all had a statistical improvement in questionnaire 
scores at 6­month follow­up.
However, as our study demonstrates there is a paucity in RCTs 
evaluating the role of PRP injections in PT. We were able to iden­
tify only 2 such studies and these differed in the PRP regime they 
administered and in the control group they utilised. Vetrano et 
al.13) found that both PRP injections and ESWT improved the 
VISA­P score at 2, 6, and >12 months (p<0.005 for all). There 
was no significant difference in the scores at baseline and 2 
months; however, there was significant difference between the 
groups at 6 months (PRP injection group, 86.7±14.2 vs. ESWT 
group, 73.7±19.9; p=0.014) and 12 months of follow­up (91.3±9.9 
vs. 77.6±19.9; p=0.026). Dragoo et al.12) found the VISA­P scores 
of the PRP group had improved significantly more than the dry 
needling group at 12 weeks (p=0.02); however, the difference be­
tween the two groups was not significant at >26 weeks (p=0.66). 
The visual analog scale (VAS) score for pain was also used as 
an outcome measure in both included studies; however, this is 
not a specific questionnaire for PT. Vetrano et al.13) showed that, 
similarly to the VISA­P score, there was improvement in the VAS 
scores for 2 months, albeit not significant (p=3.58), but there was 
significant difference between the VAS scores at 6 months (PRP 
injection group, 2.4±1.9 vs. ESWT group, 3.9±2.3; p=0.028) and 
12 months (1.5±1.7 vs 3.2±2.4; p=0.009). In the Dragoo et al.12) 
study, the VAS pain score improved for both the dry needling 
and PRP groups at 12 and >26 weeks; however, there was no sig­
nificant difference between the two groups at either follow­up (12 
weeks, p=0.13; >26 weeks, p=0.96).
It is of interest that Dragoo et al.12) found significant early (12 
week) improvements in scores between the PRP and dry needling 
groups, but no significant differences at the late term follow­up 
(>26 weeks). In contrast, Vetrano et al.13) found no significant 
difference between PRP and ESWT at early (2 month) follow­
up, but the PRP group scored significantly better on VISA­P 
and VAS at 6 and 12 months. One possible explanation for these 
contrasting findings could be the number of PRP injections 
given: the Dragoo et al.12) PRP group received one PRP injection, 
whereas in the study by Vetrano et al.13), the PRP group received 
two injections two weeks apart. It is possible that two PRP injec­
tions lead to an increased and prolonged inflammatory response, 
which takes a longer time to settle and allow clinical improve­
ment. 
When the results of the 2 studies were combined through a 
meta­analysis, there was no significant difference in mean VISA­
P scores between PRP injection and control at early assessment 
(2 or 3 months) but PRP was statistically better than control with 
regards to VISA­P scores at longer follow­up (at 6 months or 
more than 6 months), suggesting that PRP is a viable alternative 
to other non­surgical options.
The main limitation of this meta­analysis is that there are only 
2 trials included, both of which were small in size and showed 
substantial heterogeneity with regards to the regime of PRP injec­
tions and type of control group used. The follow­up in our study 
was limited to 6 months or “6 months or more”, and it would be 
beneficial to be able to compare outcomes further down the line 
with a follow­up at 12 months, etc. Nevertheless, meta­analyses 
are useful even in the presence of a small number of studies in 
that they allow pooling of data and potentially an early identifi­
cation of a beneficial or otherwise effect, whilst larger trials are 
awaited.
It is also possible that the difference at 6 months between PRP 
and control maybe due to some other factors other than the PRP 
injection itself. However, we feel this is less likely to be the cause 
of the observed difference, as patients were randomly assigned 
to the treatment and control groups, which would help deal with 
any unknown confounders. In addition, both groups received 
similar treatments other than the PRP injection–i.e. the same 
course of physiotherapy/exercise regime to follow. 
Hence, within the limitations of this study, our results suggest 
that PRP does seem to be superior for refractory PT over other 
established non­surgical treatments (such as dry­needling and 
ESWT) at 6 months post treatment. Larger RCTs comparing 
PRP versus other established treatments in PT are needed. In the 
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meantime, however, based on our results we would recommend 
the use of PRP in the treatment of PT. 
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